IFNB1 and myelodysplastic syndrome: We next treated primary MDS specimens (n = 3) with ML-60218, which significantly reduced R-loops (P = 0.0381) (Figure 5E), in addition to IFNB1 and SAMD9L, but not CXCL10 expression (IFNB1, P = 0.0050; SAMD9L, P = 0.0150) (Figure 5F).